These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

814 related items for PubMed ID: 28839341

  • 1. Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder.
    Josiassen RC, Kane JM, Liang GS, Burke J, O'Brien CF.
    Psychopharmacol Bull; 2017 Aug 01; 47(3):61-68. PubMed ID: 28839341
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder.
    Correll CU, Josiassen RC, Liang GS, Burke J, O'Brien CF.
    Psychopharmacol Bull; 2017 Aug 01; 47(3):53-60. PubMed ID: 28839340
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia.
    Hauser RA, Factor SA, Marder SR, Knesevich MA, Ramirez PM, Jimenez R, Burke J, Liang GS, O'Brien CF.
    Am J Psychiatry; 2017 May 01; 174(5):476-484. PubMed ID: 28320223
    [Abstract] [Full Text] [Related]

  • 5. The effects of valbenazine on tardive dyskinesia in patients with a primary mood disorder.
    McIntyre RS, Calabrese JR, Nierenberg AA, Farahmand K, Yonan C, Siegert S, Burke J.
    J Affect Disord; 2019 Mar 01; 246():217-223. PubMed ID: 30583148
    [Abstract] [Full Text] [Related]

  • 6. The Effects of Valbenazine in Participants with Tardive Dyskinesia: Results of the 1-Year KINECT 3 Extension Study.
    Factor SA, Remington G, Comella CL, Correll CU, Burke J, Jimenez R, Liang GS, O'Brien CF.
    J Clin Psychiatry; 2017 Mar 01; 78(9):1344-1350. PubMed ID: 29141124
    [Abstract] [Full Text] [Related]

  • 7. A Phase 3, 1-Year, Open-Label Trial of Valbenazine in Adults With Tardive Dyskinesia.
    Marder SR, Singer C, Lindenmayer JP, Tanner CM, Comella CL, Verghese C, Jimenez R, Liang GS, Burke J, OʼBrien CF.
    J Clin Psychopharmacol; 2019 Mar 01; 39(6):620-627. PubMed ID: 31688452
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Efficacy and Safety of Valbenazine in Japanese Patients With Tardive Dyskinesia and Schizophrenia/Schizoaffective Disorder or Bipolar Disorder/Depressive Disorder: Primary Results and Post Hoc Analyses of the J-KINECT Study.
    Nagano M, Susuta Y, Masui H, Watanabe Y, Watanabe K.
    J Clin Psychopharmacol; 2019 Mar 01; 44(2):107-116. PubMed ID: 38421921
    [Abstract] [Full Text] [Related]

  • 10. The effects of valbenazine on tardive dyskinesia in older and younger patients.
    Sajatovic M, Alexopoulos GS, Burke J, Farahmand K, Siegert S.
    Int J Geriatr Psychiatry; 2020 Jan 01; 35(1):69-79. PubMed ID: 31617235
    [Abstract] [Full Text] [Related]

  • 11. Characterizing Treatment Effects of Valbenazine for Tardive Dyskinesia: Additional Results From the KINECT 3 Study.
    Correll CU, Cutler AJ, Kane JM, McEvoy JP, Liang GS, O'Brien CF.
    J Clin Psychiatry; 2018 Dec 18; 80(1):. PubMed ID: 30695293
    [Abstract] [Full Text] [Related]

  • 12. Single Dose and Repeat Once-Daily Dose Safety, Tolerability and Pharmacokinetics of Valbenazine in Healthy Male Subjects.
    Luo R, Bozigian H, Jimenez R, Loewen G, O'Brien CF.
    Psychopharmacol Bull; 2017 Aug 01; 47(3):44-52. PubMed ID: 28839339
    [Abstract] [Full Text] [Related]

  • 13. Cardiovascular Profile of Valbenazine: Analysis of Pooled Data from Three Randomized, Double-Blind, Placebo-Controlled Trials.
    Thai-Cuarto D, O'Brien CF, Jimenez R, Liang GS, Burke J.
    Drug Saf; 2018 Apr 01; 41(4):429-440. PubMed ID: 29218680
    [Abstract] [Full Text] [Related]

  • 14. A long-term, open-label study of valbenazine for tardive dyskinesia.
    Lindenmayer JP, Verghese C, Marder SR, Burke J, Jimenez R, Siegert S, Liang GS, O'Brien CF.
    CNS Spectr; 2021 Aug 01; 26(4):345-353. PubMed ID: 32419679
    [Abstract] [Full Text] [Related]

  • 15. Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials.
    Solmi M, Pigato G, Kane JM, Correll CU.
    Drug Des Devel Ther; 2018 Aug 01; 12():1215-1238. PubMed ID: 29795977
    [Abstract] [Full Text] [Related]

  • 16. Valbenazine for Tardive Dyskinesia.
    Freudenreich O, Remington G.
    Clin Schizophr Relat Psychoses; 2017 Aug 01; 11(2):113-119. PubMed ID: 28742396
    [Abstract] [Full Text] [Related]

  • 17. Valbenazine-induced parkinsonism.
    Akbar U, Kim DS, Friedman JH.
    Parkinsonism Relat Disord; 2020 Jan 01; 70():13-14. PubMed ID: 31785443
    [No Abstract] [Full Text] [Related]

  • 18. Treatment of tardive dyskinesia with tetrabenazine or valbenazine: a systematic review.
    Caroff SN, Aggarwal S, Yonan C.
    J Comp Eff Res; 2018 Feb 01; 7(2):135-148. PubMed ID: 28965423
    [Abstract] [Full Text] [Related]

  • 19. Valbenazine as the first and only approved treatment for adults with tardive dyskinesia.
    Sarva H, Henchcliffe C.
    Expert Rev Clin Pharmacol; 2018 Mar 01; 11(3):209-217. PubMed ID: 29338466
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of valbenazine in Japanese patients with tardive dyskinesia: A multicenter, randomized, double-blind, placebo-controlled study (J-KINECT).
    Horiguchi J, Watanabe K, Kondo K, Iwatake A, Sakamoto H, Susuta Y, Masui H, Watanabe Y.
    Psychiatry Clin Neurosci; 2022 Nov 01; 76(11):560-569. PubMed ID: 36114799
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.